6-Hydrogen-8-Methylquinolones Active Against Replicating and Non-replicating Mycobacterium tuberculosis

Chemical Biology and Drug Design

Volumn 80, Issue 5, 2012, Pages 781-786

  Tabarrini, Oriana ^a   Sabatini, Stefano ^a   Massari, Serena ^a   Pieroni, Marco ^a,c   Franzblau, Scott G ^b   Cecchetti, Violetta ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c UNIVERSITY OF PARMA   (Italy)

Author keywords

6 desfluoroquinolones; Antitubercular agents; Multidrug resistance; Non replicating bacteria; Quinolone SAR

Indexed keywords

6 HYDROGEN 8 METHYLQUINOLONE DERIVATIVE; MOXIFLOXACIN; QUINOLONE DERIVATIVE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTITUBERCULAR AGENTS; CERCOPITHECUS AETHIOPS; DRUG RESISTANCE, MULTIPLE; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; QUINOLINES; STRUCTURE-ACTIVITY RELATIONSHIP; TUBERCULOSIS; VERO CELLS;

MYCOBACTERIUM TUBERCULOSIS;

EID: 84867232920     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/cbdd.12022     Document Type: Article

References (34)

1. Lienhardt C., Vernon A., Raviglione M.C. (2010) New drugs and new regimens for the treatment of tuberculosis: review of the drug development pipeline and implications for national programmes. Curr Opin Pulm Med;16:186-193.
2. Ma Z., Lienhardt C., Mcilleron H., Nunn A.J., Wang X. (2010) Global tuberculosis drug development pipeline: the need and the reality. Lancet;357:2100-2109.
3. Gillespie S.H., Billington O. (1999) Activity of moxifloxacin against Mycobacteria. J Antimicrob Chemother;4:393-395.
4. Fung-Tome J., Minassian B., Kolck B., Washo T., Huczko E., Bonner D. (2000) In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin. J Antimicrob Chemother;45:437-446.
5. Moadebi S., Harder C. (2007) Fluoroquinolones for the treatment of pulmonary tuberculosis. Drugs;67:2077-2099.
6. Blumberg H.M., Burman W.J., Chaisson R.E., Daley C.L., Etkind S.C., Friedman L.N., Fujiwara P. et al. (2003) American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med;167:603-662.
7. Koul A., Arnoult E., Lounis N., Guillemont J., Andries K. (2011) The challenge of new drug discovery for tuberculosis. Nature;469:483-490.
8. Rodriguez J.C., Ruiz M., Climent A., Lopez M., Royo G. (2001) In vitro activity of four quinolones against Mycobacterium tuberculosis. Int J Antimicrob Agents;17:229-231.
9. Rodriguez J.C., Ruiz M., Lopez M., Royo G. (2002) In vitro activity of moxifloxacin, levofloxacin, gatifloxacin, and linezolid against Mycobacterium tuberculosis. Int J Antimicrob Agents;20:464-467.
10. Shandil R.K., Jayaram R., Kaur P., Gaonkar S., Suresh B.L., Mahesh B.N., Jayashree R., Nandi V., Bharath S., Balasubramanian V. (2007) Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. Antimicrob Agents Chemother;51:576-582.
11. Bernardo J., Yew W.W. (2009) How are we creating fluoroquinolone-resistant tuberculosis? Am J Respir Crit Care Med;180:288-289.
12. Devasia R.A., Blackman A., Gebretsadik T., Griffin M., Shintani A., May C., Smith T., Hooper N., Maruri F., Warkentin J., Mitchel E., Sterling T.R. (2009) Fluoroquinolone resistance in Mycobacterium tuberculosis: the effect of duration and timing of fluoroquinolone exposure. Am J Respir Crit Care Med;180:365-370.
13. Ginsburg A.S., Grosset J.H., Bishai W.R. (2003) Fluoroquinolones, tuberculosis, and resistance. Lancet Infect Dis;3:432-442.
14. Webster D., Long R., Shandro C., Petipas J., Leblanc J., Davidson R., Fanning A. (2010) Fluoroquinolone resistance in renale isolates of Mycobacterium tuberculosis. Int J Tuberc Lung Dis;14:217-222.
15. Kam K.M., Yip C.W., Cheung T.L., Tang H.S., Leung O.C., Chan M.Y. (2006) Stepwise decrease in moxifloxacin susceptibility amongst clinical isolates of multidrug-resistant Mycobacterium tuberculosis: correlation with ofloxacin susceptibility. Microb Drug Res;12:7-11.
16. Cheng A.F.B., Yew W.W., Chan E.W.C., Chin M.L., Hu M.M.M., Chan R.C.Y. (2004) Multiplex PCR amplimer conformation analysis for rapid detection of gyrA mutations in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates. Antimicrob Agents Chemother;48:596-601.
17. Cecchetti V., Clementi S., Cruciani G., Fravolini A., Pagella P.G., Savino A., Tabarrini O. (1995) 6-Aminoquinolones: a new class of quinolone antibacterials? J Med Chem;39:973-982.
18. Wise R., Pagella P.G., Cecchetti V., Fravolini A., Tabarrini O. (1995) In vitro activity of MF 5137, a new potent 6-aminoquinolone. Drugs;49:272-273.
19. Cecchetti V., Fravolini A., Lorenzini M.C., Tabarrini O., Terni P., Xin T. (1996) Studies on 6-aminoquinolones: synthesis and antibacterial evaluation of 6-amino-8-methylquinolones. J Med Chem;39:436-445.
20. Cecchetti V., Fravolini A., Palumbo M., Sissi C., Tabarrini O., Terni P., Xin T. (1996) Potent 6-desfluoro-8-methylquinolones as new lead compounds in antibacterial chemotherapy. J Med Chem;39:4952-4957.
21. Cecchetti V., Tabarrini O., Sabatini S., Miao H., Filipponi E., Fravolini A. (1999) Studies on 6-aminoquinolones: synthesis and antibacterial evaluation of 6-amino-8-ethyl- and 6-amino-8-methoxyquinolones. Bioorg Med Chem;7:2465-2471.
22. Tabarrini O., Sissi C., Fravolini A., Palumbo M. (2000) 6-Hydroxy derivative as new desfluoroquinolone (DFQ): synthesis and DNA-binding study. Nucleos Nucleot Nucl;19:1327-1336.
23. Jun N., Hideto F., Hisamitsu H., Hisato S., Wakao I., Tadashi A. (1993) Antibacterial 6-fluoro-quinolones having an oxime group on the substituent in position 7. EP 541085 A1.
24. Collins L., Franzblau S.G. (1997) Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium. Antimicrob Agents Chemother;41:1004-1009.
25. Cho S.H., Warit S., Wan B., Hwang C.H., Pauli G.F., Franzblau S.G. (2007) Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis. Antimicrob Agents Chemother;51:1380-1385.
26. Falzari K., Zhu Z., Pan D., Liu H., Hongmanee P., Franzblau S.G. (1997) In vitro and in vivo activities of macrolide derivatives against Mycobacterium tuberculosis. Antimicrob Agents Chemother;41:1004-1009.
27. Cecchetti V., Parolin C., Moro S., Pecere T., Filipponi E., Callistri A., Tabarrini O., Gatto B., Palumbo M., Fravolini A., Palù G. (2000) 6-Aminoquinolones as new potential anti-HIV agents. J Med Chem;43:3799-3802.
28. Tabarrini O., Stevens M., Cecchetti V., Sabatini S., Dell'uomo M., Manfroni G., Palumbo M., Pannecouque C., De Clercq E., Fravolini A. (2004) Structure modifications of 6-aminoquinolones with potent anti-HIV activity. J Med Chem;47:5567-5578.
29. Tabarrini O., Massari S., Cecchetti V. (2010) 6-Desfluoroquinolones as HIV-1 Tat-mediated transcription inhibitors. Future Med Chem;2:1161-1180.
30. Pucci M.J., Ackerman M., Thanassi J.A., Shoen C.M., Cynamon M.H. (2010) In vitro antituberculosis activities of ACH-702, a novel isothiazoloquinolone, against quinolone-susceptible and quinolone-resistant isolates. Antimicrob Agents Chemother;54:3478-3480.
31. Alangaden G.J., Lerner S.A. (1997) The clinical use of fluoroquinolones for the treatment of mycobacterial diseases. Clin Infect Dis;25:1213-1221.
32. Wiles J.A., Bradbury B.J., Pucci M.J. (2010) New quinolone antibiotics: a survey of the literature from 2005 to 2010. Expert Opin Ther Patents;20:1295-1319.
33. Feng L.S., Liu M.L., Zhang S., Chai Y., Wang B., Zhang Y.B., Lv K., Guan Y., Guo H.Y., Xiao C.L. (2011) Synthesis and in vitro antimycobacterial activity of 8-OCH(3) ciprofloxacin methylene and ethylene isatin derivatives. Eur J Med Chem;46:341-348.
34. Tan C.K., Lai C.C., Liao C.H., Chou C.H., Hsu H.L., Huang Y., Hsueh P.R. (2009) Comparative in vitro activities of the new quinolone nemonoxacin (TG-873870), gemifloxacin and other quinolones against clinical isolates of Mycobacterium tuberculosis. J Antimicrob Chemother;64:428-429.